• Registry of Patients With Hypophosphatasia

  NCT02306720

  Enrolling by invitationObservationalUpdated Feb 27, 2026
• Characteristics of Hypophosphatasia in Adult Patients in Rheumatology

  NCT06161142

  Unknown statusObservationalUpdated Dec 7, 2023
• Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)

  NCT02104219

  CompletedObservationalUpdated Apr 1, 2019
• A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)

  NCT01419028

  CompletedObservationalUpdated Apr 1, 2019
• A Prospective Sub-Study of the Global Hypophosphatasia Registry

  NCT05234567

  RecruitingObservationalUpdated Feb 9, 2026
• Characterisation of Adult-Onset Hypophosphatasia

  NCT02796885

  CompletedObservationalUpdated Nov 15, 2023

ClinicalTrials.gov ID

NCT05596539

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Overall Status

Recruiting

Study Type

Observational

Enrollment

200Estimated

Last Update Posted

Aug 5, 2026Actual

Start Date

Mar 22, 2023Actual

Primary Completion Date

Sep 2026Estimated

Completion Date

Sep 2031Estimated

Official Title

Prospective, Longitudinal, Observational Registry of Adult Patients With Hypophosphatasia

Brief Summary

The purpose of this study is to assess medical events during follow-up of adult patients having hypophosphatasia and consulting rheumatologists.

Detailed Description

Hypophosphatasia (HPP) is a rare inherited disease caused by mutations of the ALPL gene. In adult HPP, patients may suffer from fractures, pseudofractures, fracture healing complications, osteoarthritis, chondrocalcinosis, dental diseases, muscle pain and disability, but also headache, muscle weakness, ocular disease, and other symptoms. In some cases the diagnosis is severely delayed. Moreover a number of patients having such symptoms and a low level of serum alkaline phosphatase, without gene mutation can be followed by rheumatologists with difficulties in management of bone fragility and pain. The aim of this register is to describe prospectively the medical events in adult patients having hypophosphatasia, whether or not there is a proven genetic abnormality.

• Hypophosphatasia

• Data collection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• men and women,
• aged 18 and over, with no upper age limit, who have had a total alkaline phosphatase value of less than 40 IU/l on at least 3 occasions, or at least a total alkaline phosphatase value below 40 IU/L and evidence of ALPL gene polymorphism
• with at least one rheumatological symptom.

Exclusion Criteria:

• transient hypophosphatasia: absence of confirmation of a value below 40 IU/l on at least 3 samples, lack of genetic confirmation
• secondary hypophosphatasia according to the expert rheumatologist (drugs, endocrine disease, other genetic disease...).

Observational Model

Cohort

Time Perspective

Other

Lead Sponsor

Assistance Publique - Hôpitaux de ParisOTHER

Collaborators

URC-CIC Paris Descartes Necker CochinOTHER

bernad.cortet@chu-lille.fr0320444037